Vincentage Pharma

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1 receptorSmall molecule
ObesityType 2 DiabetesHypertension

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
VCT220Phase 2Type 2 Diabetes Mellitus (DM)
Est. primary completion 2027-07-01 · NCT07872436 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 May 2026Topline resultVCT220VCT220 pivotal Phase 3 topline positive
Vincentage Pharma · Source ↗

Financial reports

No financial reports recorded.